ClinicalTrials.gg
RecruitingNCT07670884Updated Aug 13, 2026

A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

A Phase 3 interventional study of HRS9531 Tablet and HRS9531 Tablet Placebo in Chronic Management of Body Weight, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
675
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.

02

Conditions studied

  • Chronic Management of Body Weight
03

In context

Lead sponsor

Fujian Shengdi Pharmaceutical Co., Ltd. is the lead sponsor of 66 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects, 18-75 years of age at the time of signing ;
  2. At screening visit, ≥ 28 kg/m2 or ≥ 24 kg/m2 with at least one weight-related comorbidity;
  3. Diet and exercise control for at least 3 months before screening visit, and the weight change does not exceed 5% within the last 3 months;
  4. Able and willing to provide a written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Presence of lab or results that may affect the evaluation of the efficacy or safety of the study drug at screening visit;
  2. Uncontrollable severe hypertension;
  3. PHQ-9 score ≥ 15;
  4. Medical history or illness that affects body weight;
  5. History of diabetes;
  6. Acute or chronic hepatitis;
  7. History of severe cardiovascular and cerebrovascular diseases within 6 months prior to screening;
  8. Any organ-system developed within 5 years;
  9. Acute infection, acute trauma, or medium to large surgery within 30 days prior to screening;
  10. Confirmed or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illness, mentally incapacitated or speech-impaired;
  11. Use of any medication or treatment that may have caused significant weight change within 90 days;
  12. History of bariatric surgery;
  13. Known or suspected to trial product(s) or related products;
  14. History of alcohol and/or substance abuse or drug abuse;
  15. History of blood donation or blood loss in the 3 months before screening, or blood transfusion in the 2 months before screening;
  16. Surgery is planned during the trial;
  17. The investigators determined that other conditions were inappropriate for participation in this clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
675 participants (estimated)

Study arms

  • Experimental
    HRS9531 Tablet Group

    HRS9531 tablet.

    Drug: HRS9531 Tablet

  • Placebo comparator
    HRS9531 Tablet Placebo Group

    HRS9531 tablet placebo.

    Drug: HRS9531 Tablet Placebo

Interventions

  • HRS9531 tablet.

  • DrugHRS9531 Tablet Placebo

    HRS9531 tablet placebo.

06

What researchers measure

Primary outcomes

  1. Percentage change from baseline in body weight after 52 weeks of treatment

    Time frame: After 52 weeks of treatment.

  2. Proportion of subjects with weight loss of ≥ 5% from baseline in body weight after 52 weeks of treatment

    Time frame: After 52 weeks of treatment.

Secondary outcomes

  1. Proportion of subjects with weight loss of ≥ 10% from baseline in body weight after 52 weeks of treatment

    Time frame: After 52 weeks of treatment.

  2. Proportion of subjects with weight loss of ≥ 15% from baseline in body weight after 52 weeks of treatment

    Time frame: After 52 weeks of treatment.

  3. Proportion of subjects with weight loss of ≥ 20% from baseline in body weight after 52 weeks of treatment

    Time frame: After 52 weeks of treatment.

  4. Change from baseline in waist circumference after 52 weeks of treatment

    Time frame: After 52 weeks of treatment.

  5. Change from baseline in body weight after 52 weeks of treatment

    Time frame: After 52 weeks of treatment.

  6. Change from baseline in BMI (Body Mass Index) after 52 weeks of treatment

    Time frame: After 52 weeks of treatment.

  7. Change from baseline in blood pressure after 52 weeks of treatment

    Time frame: After 52 weeks of treatment.

  8. Change from baseline in fasting plasma glucose after 52 weeks of treatment

    Time frame: After 52 weeks of treatment.

  9. Change from baseline in fasting serum insulin after 52 weeks of treatment

    Time frame: After 52 weeks of treatment.

  10. Change from baseline in glycosylated hemoglobin after 52 weeks of treatment

    Time frame: After 52 weeks of treatment.

  11. Change from baseline in blood lipid after 52 weeks of treatment

    Time frame: After 52 weeks of treatment.

  12. Change from baseline in blood uric acid after 52 weeks of treatment

    Time frame: After 52 weeks of treatment.

  13. Number of treatment serious adverse events (SAEs) within 57 weeks

    Time frame: Within 57 weeks.

  14. Number of treatment adverse events (AEs) within 57 weeks

    Time frame: Within 57 weeks.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Oct 2027, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jun 26, 2026
StartActual
Jul 24, 2026
Primary completionEst.
Oct 31, 2027
CompletionEst.
Nov 30, 2027
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07670884
Responsible party
Sponsor
First posted
Jun 26, 2026
Start date
Jul 24, 2026
Primary completion
Oct 31, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Aug 13, 2026

Study contacts

Danli Zhang, M.M
Contact
danli.zhang@hengrui.com
13162215826

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS9531

Start the discussion